Blog

Oxford Nanopore Technologies (LSE:ONT) has reported preliminary first-half 2026 revenue of approximately £116.5 million, with sales increasing despite a softer-than-expected performance in several international markets.

The company said revenue rose around 10% on a reported basis, or 12% at constant currency, although results were affected by weaker demand in China and the Middle East, together with the timing of customer orders in the Americas.

Regional Weakness Offsets Strong Performance Elsewhere

Oxford Nanopore delivered its strongest growth across Europe, the Middle East, Africa and India, while Clinical and BioPharma continued to be among its fastest-growing application areas.

The company’s PromethION sequencing platform was the leading contributor to product growth during the period.

Oxford Nanopore also ended the first half with liquid resources of approximately £234.5 million, providing continued financial support for its investment and expansion strategy.

Company Maintains Full-Year Outlook

Despite the slower start to the year, management has reaffirmed its guidance for constant-currency revenue growth of around 21% to 25% for 2026, including non-recurring collaboration and licensing income.

Underlying revenue growth is expected to be between approximately 16% and 20%, reflecting continued pressure in certain regional markets.

The company anticipates a significantly stronger second half, supported by increasing momentum in applied markets and the delivery of business already secured.

Oxford Nanopore also maintained its expectation of a gross margin of around 62% for the full year and continues to target adjusted EBITDA breakeven during 2027. Interim results are scheduled to be released in August.

Profitability Still a Work in Progress

While revenue continues to grow, Oxford Nanopore remains loss-making and continues to generate negative free cash flow as it invests in expanding its business.

Technical indicators also remain weak, with the shares trading below major moving averages and broader market momentum remaining negative.

However, management continues to highlight disciplined operating expenditure, improving margins and a relatively low level of leverage as factors supporting its long-term financial outlook.

About Oxford Nanopore Technologies

Oxford Nanopore Technologies develops nanopore-based sensing technology that enables real-time analysis of DNA and RNA across research, clinical, pharmaceutical and industrial applications.

Its sequencing platforms are used in more than 125 countries to support work in areas including cancer research, infectious disease, human genetics, agriculture, food safety and environmental science, with the company continuing to expand its presence across both healthcare and applied markets.

Nativo Resources (LSE:NTVO) has unveiled a revised development strategy for its La Patona Gold Ore Processing Plant in Peru, splitting the project into three construction phases designed to reduce upfront capital requirements and bring the operation into production more quickly.

The phased approach is intended to accelerate initial cash flow while lowering execution risk as the company progresses towards becoming a gold producer.

Three-Stage Rollout Targets Earlier Cash Generation

Under the updated plan, the La Patona processing facility will be built in stages, beginning with an initial throughput capacity of 70 tonnes per day before expanding to 110 tonnes per day and ultimately reaching 350 tonnes per day as operating cash flow supports future growth.

The plant will incorporate both flotation and cyanidation processing circuits, together with on-site smelting facilities, allowing Nativo to process gold ore through multiple recovery methods.

Management said the revised structure enables the company to match expansion with operational performance, limiting capital exposure during the early stages of the project.

Funding Strategy Combines External Finance and Operating Cash Flow

The first phase of development is expected to require capital expenditure of approximately US$2.03 million before contingency costs.

Nativo intends to fund the initial build using a combination of project finance, royalty streaming agreements and equity funding. Subsequent expansion phases are expected to rely largely on cash generated by the operation itself.

According to the company, engineering work and cost estimates have now been completed, leaving the project ready for construction. First gold production remains targeted for late 2026, marking an important step in Nativo’s transition from exploration and development into commercial production.

Financial Position Remains an Area to Watch

Despite progress at La Patona, Nativo continues to face financial challenges typical of companies at the development stage.

The business currently generates no revenue and continues to report widening losses, negative shareholders’ equity and ongoing cash outflows while advancing its projects.

Technical indicators also remain weak, with the shares trading below major moving averages, while valuation continues to be affected by negative earnings and the absence of a dividend.

About Nativo Resources Plc

Nativo Resources Plc is a precious metals company focused on gold mining and processing projects in Peru, including the Tesoro Gold Concession.

Its strategy combines primary gold production with the processing of third-party ore and the recovery of gold from historical tailings, providing multiple potential revenue streams.

The La Patona Gold Ore Processing Plant is expected to process both company-owned and externally sourced ore, positioning the business as a regional processing hub while supporting its long-term growth strategy in Peru’s gold sector.

Alien Metals (LSE:UFO) has reported encouraging exploration progress at the Munni Munni platinum group metals (PGE), copper and nickel project in Western Australia, where the company holds a 30% free-carried interest alongside a strategic shareholding in project operator GreenTech Metals.

The latest technical review has identified several new exploration targets that could expand the project’s potential for copper, nickel and platinum group metal discoveries.

Independent Review Highlights High-Priority Targets

The updated geological assessment, completed by independent geochemical specialist Dr Scott Halley, has introduced a revised exploration model for the Munni Munni project.

The review identified a number of priority target areas along the project’s basal contact, together with a large copper anomaly associated with magnetite-rich geological zones.

According to the company, these features indicate previously untested potential for copper-nickel-platinum group metal sulphide mineralisation and will help guide the next phase of exploration.

Future work is expected to include geophysical surveys followed by drilling programmes aimed at testing the newly identified targets.

Alien said the results could enhance the long-term value of both its joint venture interest and its equity investment in GreenTech Metals as demand for battery metals and platinum group metals continues to grow.

Diversified Pilbara Portfolio Provides Commodity Exposure

Beyond Munni Munni, Alien Metals maintains a diversified portfolio of exploration and development assets across Western Australia’s Pilbara region.

Its flagship asset is the Hancock Iron Ore Project, while the company also has exposure to silver and platinum group metals through its various joint ventures and strategic investments.

This diversified portfolio provides leverage to several commodity markets, including iron ore, copper, nickel and precious metals.

Financial Performance Remains Under Pressure

Despite continued exploration progress, Alien Metals continues to operate without revenue and remains in a development phase, resulting in ongoing losses and sustained cash outflows.

Market indicators also remain weak, with the shares trading below key moving averages and technical measures continuing to reflect bearish momentum.

While valuation metrics offer some support, the company does not currently pay a dividend, and investors remain focused on exploration success and future project development.

About Alien Metals Ltd

Alien Metals Ltd is an AIM-listed exploration and development company focused on iron ore and critical minerals projects in Western Australia’s Pilbara region.

Its principal asset is the 90%-owned Hancock Iron Ore Project, which hosts a JORC-compliant mineral resource and is being advanced towards potential production.

The company also holds interests in the Munni Munni PGE-copper-nickel joint venture and the Elizabeth Hill Silver Project, while maintaining equity stakes in GreenTech Metals and West Coast Silver.

Alien’s strategy combines project development, exploration and selective investment in partner companies to build exposure to a range of commodities, including iron ore, platinum group metals, copper, nickel, silver and gold.

Helix Exploration PLC (LSE:HEX) has completed the acquisition of the Keyes Helium Complex in Oklahoma, marking a significant step in its strategy to become a fully integrated helium producer and liquefier in the United States.

The $11 million transaction adds helium purification and liquefaction capabilities to the company’s existing upstream production at its Rudyard Project in Montana, allowing Helix to operate across the entire helium supply chain from extraction through to liquid helium delivery.

Acquisition Strengthens Integrated Helium Strategy

With the addition of the Keyes facility, Helix becomes an independent U.S. liquefier capable of processing helium from both its own production and third-party suppliers.

Management believes the acquisition will enable the company to capture greater value across the production chain by retaining processing margins that would otherwise be outsourced. The expanded platform is also expected to support future growth while strengthening Helix’s position in the North American helium market.

The company said the transaction enhances its ability to diversify helium supply sources, increase operational flexibility and create additional long-term value as demand for helium continues to grow across industrial, healthcare and technology applications.

Financial Challenges Remain Despite Strategic Progress

While the acquisition represents an important strategic milestone, Helix continues to face financial headwinds as it advances its growth plans.

The company remains pre-revenue and continues to report operating losses alongside increasing free cash flow outflows as it invests in developing its assets.

Although Helix has no debt, providing balance sheet strength, the absence of earnings and dividend support continues to weigh on valuation, while technical indicators remain negative with the share price trading below key moving averages.

About Helix Exploration PLC

Helix Exploration PLC is a U.S.-focused helium production and liquefaction company listed on the London Stock Exchange.

Its flagship Rudyard Project in Montana became the state’s first producing helium field when commercial production commenced in February 2026. The project contains multiple stacked helium-bearing reservoirs and includes on-site processing infrastructure.

The acquisition of the Keyes Helium Complex, one of only six operating helium liquefaction facilities in the United States, gives Helix ownership of both production and downstream processing assets. The company is focused on building a fully integrated helium business supported by low-cost production, established infrastructure and opportunities for future expansion.

Potter & Moore PLC (LSE:PAM), formerly Creightons PLC, delivered broadly unchanged annual revenue for the year ended 31 March 2026, with strong growth in its Private Label business helping to offset weaker contract manufacturing activity linked to one major customer.

The beauty and well-being products manufacturer also reported an improvement in gross margin following operational efficiencies and procurement savings, although higher employment costs weighed on earnings during the period.

Private Label Growth Supports Stable Performance

Revenue for the financial year came in at £53.8 million, broadly in line with the previous year, as 9% growth in Private Label sales and new customer wins balanced a significant reduction in contract manufacturing volumes.

Gross margin increased to 44.9%, reflecting continued progress in manufacturing efficiency, sourcing improvements and operational cost controls.

Despite the stronger margin, EBITDA and profit before tax declined as the business absorbed higher labour costs following increases to both the National Living Wage and National Insurance contributions.

The company also strengthened its financial position, ending the year with higher net cash, while the board recommended an increased final dividend for shareholders.

Business Investing in Productivity and Technology

During the year, Potter & Moore continued to invest in projects designed to improve efficiency and support future expansion.

These initiatives included the rollout of a new warehouse management system, greater use of digital manufacturing tools and AI-powered artwork automation. The company also expanded its sales team as it seeks to accelerate growth across its core markets.

Management has completed a strategic review that sets out priorities for the next five years, with a focus on expanding the Private Label business, streamlining the company’s portfolio of brands, increasing automation and artificial intelligence across operations, and exploring opportunities in the wider wellness sector.

The recent corporate rebranding from Creightons PLC to Potter & Moore is intended to better align the listed company with its established trading identity and improve recognition among customers and investors.

Board Refresh and Operational Plans Continue

Potter & Moore is also making changes to its board, with two directors stepping down at the upcoming annual meeting and a recruitment process underway for a new independent non-executive director.

Alongside the governance changes, the company is reviewing how best to optimise its manufacturing facilities while preparing to introduce a new core enterprise resource planning (ERP) system incorporating AI capabilities. Management expects the investment to enhance productivity and support sustainable long-term growth.

Outlook Supported by Strong Balance Sheet

The company’s outlook continues to benefit from a solid balance sheet and what it considers an attractive valuation, supported by a relatively low price-to-earnings ratio.

However, weaker free cash flow growth remains an area to monitor, while technical indicators continue to point to a cautious near-term market trend despite the group’s underlying financial strength.

About Potter & Moore PLC

Potter & Moore PLC is a UK-based beauty and well-being products company that develops, manufactures and supplies both Private Label and owned brands to retailers and commercial partners.

The group focuses on research-led product innovation, expanding its leadership in the Private Label market and pursuing new opportunities within the growing wellness sector.

PureTech Health’s (LSE:PRTC) founded entity, Celea Therapeutics, has enrolled the first patient in SURPASS-IPF, a global Phase 3 clinical trial designed to compare its investigational therapy, deupirfenidone, directly against the approved treatment pirfenidone in patients with idiopathic pulmonary fibrosis (IPF).

The randomized study will follow around 1,100 participants over a 52-week period and is the first industry-sponsored Phase 3 IPF trial to evaluate two active therapies without a placebo arm. Every patient enrolled will receive treatment, with the primary objective of determining whether deupirfenidone offers superior preservation of lung function compared with pirfenidone.

Phase 3 Programme Builds on Earlier Clinical Success

The launch of SURPASS-IPF follows Celea’s recent $180 million financing and marks the next stage in the development of deupirfenidone after encouraging Phase 2b results.

Previous clinical data indicated the investigational therapy may significantly reduce the rate of lung function decline while offering an improved tolerability profile compared with existing antifibrotic treatments. The company believes these characteristics could help address barriers that have limited the adoption of current therapies.

Top-line data from the Phase 3 study are anticipated during the second half of 2029. According to the company, discussions with U.S. regulators suggest that a single successful Phase 3 trial may be sufficient to support a regulatory submission, making SURPASS-IPF an important milestone for both Celea Therapeutics and PureTech.

Financial Position Remains a Key Consideration

Despite continued progress across its clinical pipeline, PureTech’s financial profile remains constrained by ongoing operating losses, negative free cash flow and relatively modest revenue generation.

These challenges are partly balanced by a solid balance sheet, while recent management updates have highlighted advances across the company’s development portfolio, improvements in operating losses and available funding runway.

Nevertheless, execution and future financing requirements remain important factors as the company advances its late-stage clinical programmes. Valuation also continues to be affected by the absence of earnings and dividend support, while technical indicators remain broadly neutral.

About PureTech Health

PureTech Health is a London-listed biotherapeutics company that creates and develops businesses focused on innovative treatments for serious diseases using its hub-and-spoke operating model.

One of its founded entities, Boston-based Celea Therapeutics, is developing therapies for respiratory diseases, including idiopathic pulmonary fibrosis.

Its lead candidate, deupirfenidone (LYT-100), is a next-generation deuterated version of pirfenidone designed to improve both efficacy and tolerability. The therapy has received Orphan Drug Designation in both the United States and the European Union and is currently in Phase 3 development as a potential new treatment option for IPF patients.

Financial markets are once again pricing in higher geopolitical risk after renewed military exchanges between the United States and Iran cast doubt on the durability of the recent ceasefire.

President Donald Trump stated that the ceasefire is “over” and described ongoing diplomatic efforts as “a waste of time,” increasing uncertainty over the outlook for the region.

Energy Markets React First

Oil prices have responded quickly to the renewed tensions, reversing much of their recent decline.

WTI crude briefly traded below $70 a barrel before rebounding above $74 as investors reinstated a geopolitical risk premium. Any sustained increase in energy prices could revive inflation concerns and alter expectations for global monetary policy.

Bond Markets Reflect Inflation Concerns

The move has also been reflected in U.S. government bonds, with the 10-year Treasury yield climbing to 4.56%.

Higher yields suggest investors are reassessing the inflation outlook and the possibility that the Federal Reserve may need to keep interest rates elevated for longer.

Although stock markets have so far remained resilient, further escalation in the Middle East could increase volatility across global financial assets.

Investors Await the Next Catalyst

Markets continue to expect no policy change at the Federal Reserve’s July meeting, but expectations for additional tightening later this year remain sensitive to incoming inflation data and energy prices.

Oil prices, Treasury yields and geopolitical developments are therefore likely to remain the key indicators shaping investor sentiment over the coming weeks.

As Yogi Berra famously observed, “It ain’t over till it’s over,” and financial markets continue to reflect that uncertainty.